Skip to main content

Market Overview

Shares Of Chembio Falling After Co. Fails To Provide Timeline On Product Deployment


Shares of biotech Chembio Diagnostics (NASDAQ: CEMI)  got a dramatic boost in the arm Monday morning. The Medford, NY, based firm announced a partnership with Integrated BioTherapeutics, Inc to develop and continue to maintain “...exclusive rights to any POC (Point of Care) product developed through [the company's] agreement.”   


Chembio will combine its patented DPP(R) technology with IBT's proprietary Ebola reagents to develop POC diagnostic tests for Ebola and febrile illness.


Benzinga placed a call to Chembio’s Investor Relations to get color on the timeline of product deployment, but have yet to hear back.


Concerns on the timeline, and costs of product deployment is providing resistance to the upside.

The company did offer a press release on Tuesday; however, this was related to tests for Dengue Fever and a specific type of cancer and not related to the item from Monday.

Shares, as of printing,  down 6% and trading  is at a robust pace. Volume is up over 60 percent, when compared to CEMI’s average 3 month trading volume.


Related Articles (CEMI)

View Comments and Join the Discussion!

Posted-In: News FDA Movers

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at